share_log

We Think WuXi AppTec (SHSE:603259) Can Stay On Top Of Its Debt

We Think WuXi AppTec (SHSE:603259) Can Stay On Top Of Its Debt

我們認爲藥明康德 (SHSE:603259) 可以應對其債務
Simply Wall St ·  12/03 16:46

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company is, we always like to look at its use of debt, since debt overload can lead to ruin. We note that WuXi AppTec Co., Ltd. (SHSE:603259) does have debt on its balance sheet. But the more important question is: how much risk is that debt creating?

禾倫·巴菲特著名地說過:『波動性遠非與風險同義。』當我們考慮一家公司的風險時,我們總是喜歡關注其債務的使用,因爲債務過重可能導致毀滅。我們注意到藥明康德有限公司(SHSE:603259)確實在其資產負債表上有債務。但更重要的問題是:這些債務產生了多少風險?

When Is Debt A Problem?

什麼時候負債才是一個問題?

Debt is a tool to help businesses grow, but if a business is incapable of paying off its lenders, then it exists at their mercy. In the worst case scenario, a company can go bankrupt if it cannot pay its creditors. While that is not too common, we often do see indebted companies permanently diluting shareholders because lenders force them to raise capital at a distressed price. Of course, debt can be an important tool in businesses, particularly capital heavy businesses. The first step when considering a company's debt levels is to consider its cash and debt together.

債務是幫助企業成長的一種工具,但如果一個企業無法償還其貸款人,則其存在於貸款人的恩惠之下。在最糟糕的情況下,公司如果無法償還其債權人就會破產。雖然這不是太常見的情況,但我們經常會看到因貸款人強迫它們以窘迫的價格籌集資本而造成負債公司永久地稀釋股東。當然,債務可以是企業中的重要工具,特別是對於資本較多的企業。在考慮公司的債務水平時,第一步是考慮現金和債務的總體情況。

What Is WuXi AppTec's Net Debt?

藥明康德的淨債務是多少?

As you can see below, at the end of September 2024, WuXi AppTec had CN¥5.62b of debt, up from CN¥5.00b a year ago. Click the image for more detail. But on the other hand it also has CN¥14.1b in cash, leading to a CN¥8.44b net cash position.

正如您在下面看到的,截至2024年9月底,藥明康德的債務爲56.2億人民幣,上年爲50億人民幣。點擊圖片獲取更多詳細信息。但另一方面,它還有141億人民幣的現金,形成了84.4億人民幣的淨現金頭寸。

big
SHSE:603259 Debt to Equity History December 4th 2024
SHSE:603259 債務與權益歷史 2024年12月4日

A Look At WuXi AppTec's Liabilities

看一看藥明康德的負債

The latest balance sheet data shows that WuXi AppTec had liabilities of CN¥12.9b due within a year, and liabilities of CN¥5.73b falling due after that. Offsetting these obligations, it had cash of CN¥14.1b as well as receivables valued at CN¥9.55b due within 12 months. So it can boast CN¥4.95b more liquid assets than total liabilities.

最新的資產負債表數據顯示,藥明康德的負債爲129億人民幣,在一年內到期,還有57.3億人民幣的負債在此之後到期。爲了抵消這些負債,它擁有141億人民幣的現金以及在12個月內到期的應收賬款,價值爲95.5億人民幣。因此,它可以自豪地擁有比總負債多出49.5億人民幣的流動資產。

This surplus suggests that WuXi AppTec has a conservative balance sheet, and could probably eliminate its debt without much difficulty. Simply put, the fact that WuXi AppTec has more cash than debt is arguably a good indication that it can manage its debt safely.

這一盈餘表明藥明康德的資產負債表保守,可能能夠輕鬆消除其債務。簡單來說,藥明康德擁有的現金超過債務,這無疑是一個良好信號,表明它可以安全地管理其債務。

But the other side of the story is that WuXi AppTec saw its EBIT decline by 6.8% over the last year. If earnings continue to decline at that rate the company may have increasing difficulty managing its debt load. There's no doubt that we learn most about debt from the balance sheet. But ultimately the future profitability of the business will decide if WuXi AppTec can strengthen its balance sheet over time. So if you're focused on the future you can check out this free report showing analyst profit forecasts.

但事情的另一面是,藥明康德的EBIT在過去一年中下降了6.8%。如果收益繼續以這種速度下降,公司可能會越來越難以管理其債務負擔。毫無疑問,我們從資產負債表中學到了大部分關於債務的知識。但最終,業務的未來盈利能力將決定藥明康德是否能夠隨着時間的推移增強其資產負債表。因此,如果你關注未來,可以查看這份顯示分析師利潤預測的免費報告。

Finally, while the tax-man may adore accounting profits, lenders only accept cold hard cash. WuXi AppTec may have net cash on the balance sheet, but it is still interesting to look at how well the business converts its earnings before interest and tax (EBIT) to free cash flow, because that will influence both its need for, and its capacity to manage debt. Looking at the most recent three years, WuXi AppTec recorded free cash flow of 48% of its EBIT, which is weaker than we'd expect. That's not great, when it comes to paying down debt.

最後,儘管稅務機關可能喜歡會計利潤,但貸方只接受冷硬現金。藥明康德的資產負債表上可能有淨現金,但看看企業如何將其利息和稅前收益(EBIT)轉化爲自由現金流也是很有意思的,因爲這將影響其管理債務的需求和能力。在過去三年中,藥明康德的自由現金流佔其EBIT的48%,這比我們預期的要弱。這在償還債務方面並不太理想。

Summing Up

總之

While we empathize with investors who find debt concerning, you should keep in mind that WuXi AppTec has net cash of CN¥8.44b, as well as more liquid assets than liabilities. So we are not troubled with WuXi AppTec's debt use. The balance sheet is clearly the area to focus on when you are analysing debt. But ultimately, every company can contain risks that exist outside of the balance sheet. To that end, you should be aware of the 1 warning sign we've spotted with WuXi AppTec .

雖然我們能理解投資者對債務的擔憂,但您應該記住,藥明康德的淨現金爲84.4億人民幣,流動資產也超過負債。因此,我們對藥明康德的債務使用並不感到困擾。在分析債務時,資產負債表顯然是需要關注的領域。但最終,每家公司都有可能存在資產負債表之外的風險。爲此,您應該注意我們發現的藥明康德的1個警告信號。

At the end of the day, it's often better to focus on companies that are free from net debt. You can access our special list of such companies (all with a track record of profit growth). It's free.

每天結束時,通常更好地關注那些沒有淨債務的公司。您可以查看我們特別名單上的這些公司(所有這些公司都有盈利增長記錄)。這是免費的。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接與我們聯繫。或者,發送電子郵件至editorial-team @ simplywallst.com。
Simply Wall St的這篇文章是一般性質的。我們僅基於歷史數據和分析師預測提供評論,使用公正的方法,我們的文章並非意在提供財務建議。這並不構成買入或賣出任何股票的建議,並且不考慮您的目標或財務狀況。我們旨在爲您帶來基於基礎數據驅動的長期聚焦分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St對提及的任何股票都沒有持倉。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論